Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Cannabidiol (Epidiolex)

Notes:

^ Adequate trial is defined as 1-month treatment duration
* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
+ AEDs for Lennox Gastaut: felbamate, valproate, topiramate, lamotrigine, rufinamide, clobazam, clonazepam, zonisamide; AEDs for Dravet Syndrome: valproate, clobazam, levetiracetam, topiramate, zonisamide, clonazepam
# Significant hepatic impairment: liver function tests (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal with bilirubin greater than 2 times upper limit of normal

Initiation (new start) criteria: Non-formulary cannabidiol (Epidiolex) will be covered on the prescription drug benefit for 6 months when the following criteria are met:

- Prescribed by a neurologist
- Patient is 2 years old or older
- Prescribed for Dravet Syndrome or Lennox-Gastaut syndrome
- Patient has failed an adequate trial^, or patient has an allergy or intolerance* to at least 2 other antiepileptic medications (AEDs) that are appropriate for diagnosis+
- No significant hepatic impairment#
- Patient is not using cannabis or other cannabis derivatives

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary cannabidiol (Epidiolex) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- See Initiation criteria

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously. Non-formulary cannabidiol (Epidiolex) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is 2 years old or older
- Prescribed for Dravet Syndrome or Lennox-Gastaut syndrome
- Patient has failed an adequate trial^, or patient has an allergy or intolerance* to at least 2 other antiepileptic medications that are appropriate for diagnosis+
- Patient is not using cannabis or other cannabis derivatives
Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Cannabidiol (Epidiolex)

**Continued use criteria (6 months after initiation):** Non-formulary cannabidiol (Epidiolex) will continue to be covered on the prescription drug benefit for **12 months** when the following criteria are met:

- Continued to be prescribed by neurologist for Dravet Syndrome or Lennox-Gastaut syndrome
- Sustained improvement in seizure control (frequency and/or severity) since starting Epidiolex as assessed and documented by neurologist
- No significant hepatic impairment
- Patient is not using cannabis or other cannabis derivatives

**Continued use criteria for patients stable on the medication:** Non-formulary cannabidiol (Epidiolex) will continue to be covered on the prescription drug benefit for **12 months** when the following criteria are met:

- Prescribed by Neurologist
- Office visit or telephone visit with neurologist within the past 12 months